Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Halozyme Therapeutics revenue increased from $196 million in 2019 to $267.6 million in 2020, a (36.5%) increase.

Annual Revenue ($)

Halozyme Therapeutics revenue was $267.59 m in FY, 2020 which is a (36.5%) year over year increase from the previous period.

Quarterly Revenue ($)

FY, 2018FY, 2019FY, 2020
Revenue$151.86 m$195.99 m$267.59 m
Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021
Revenue$56.95 m$39.15 m$46.23 m$25.35 m$55.22 m$65.32 m$89.02 m

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

Geographic Segment

Halozyme Therapeutics revenue breakdown by business segment: 33.1% from Royalties, 46.0% from Revenues under Collaborative Agreements and 20.9% from Product Sales

Halozyme Therapeutics revenue breakdown by geographic segment: 40.0% from United States, 35.9% from Switzerland, 11.4% from Ireland, 7.5% from Belgium and 5.3% from Other

FY, 2020FY, 2018FY, 2019
Royalties$88.6 m$78.98 m$69.9 m
Revenues under Collaborative Agreements$123.01 m$44.65 m$60.05 m
Product Sales$55.99 m$28.23 m$66.05 m
FY, 2020FY, 2018FY, 2019
United States$106.92 m$40.48 m$116.08 m
Switzerland$95.95 m$109.89 m$78.41 m
Other Countries$3.45 m$1.5 m$1.5 m
Ireland$30.55 m
Belgium$20.09 m
Japan$10.64 m

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu